Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.

A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. , ,  and and  c. 1639 G>A variations were observed in 62 study patients. Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on and only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants , and , and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort.